Takeda Pharmaceutical Company Limited

Pfizer Corporation

Sean Timothy Murphy

Benjamin Jones

Andre A Kiryanov

Joanne Miura

Jon Kuehler

Melinda Davis

Jason W Brown

Xiaolun Wang

Marion Lanier

Anthony Ivetac

Matthew Frank Brown

Holger Monenschein

Clarke Bentley Taylor

Edmund Lee Ellsworth

Timothy Allan Johnson

Joseph Scott Warmus

Denton Wade Hoyer

Manjinder Singh Lall

Debra Ann Sherry

Charles Francis Donovan

Jun Feng

Zacharia S Cheruvallath

Christopher McBride

John David Lawson

Holly Reichard

Huikai Sun

Maria Hopkins

Thomas Nixey

Betty Lam

Chris Limberakis

Mingnam Tang

Mallareddy Komandla

Timothy Allen Johnson

Jason Green

Philip Erickson

Huong-Thu Ton-Nu

Natasha O'rourke

Scott Olsen

Chris Lim-Berakis

Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R, R, R, R, R, R, R, X, X, Xand Xare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

Azole-fused pyridazin-3(2H)-one derivatives

Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R, R, R, R, R, X, X, X, X, X, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.

Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6

The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Indazole derivatives

The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L-L, A, B, R-R, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Hydroxamic acid derivatives useful as antibacterial agents

The present invention provides compounds of the formula:  which are useful as inhibitors of PHD and pharmaceutical compositions thereof.

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L-LA, B, R-Rand m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Growing community of inventors

Oceanside, CA, United States of America

Sean Timothy Murphy